Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Thoracic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Melanoma 1Liver Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 70Nivolumab 24Docetaxel 17Cisplatin 15Paclitaxel 13Carboplatin 12Gemcitabine 8Cetuximab 8Ipilimumab 7durvalumab 6avelumab 6atezolizumab 6Radiotherapy 6Cyclophosphamide 6spartalizumab 5Trastuzumab 5Taxes 5Pemetrexed 5Erlotinib Hydrochloride 5tremelimumab 4cemiplimab 4Specimen Handling 4Leucovorin 4Interleukin-2 4Fluorouracil 4Capecitabine 4Biopsy 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4utomilumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × C188-9 compound × Thoracic × Clear all
NCT03195699 2025-03-21

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Tvardi Therapeutics, Incorporated

Phase 1 Completed
64 enrolled
BreastDermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡